MedPal’s (AIM: MPAL) July trading update gave investors the clearest indication yet that its digital-health ambitions are being supported by real operating revenue. The company reported an annualised recurring revenue run rate of more than £8.6 million, up over 70% in two months and from a standing start when pharmacy dispensing began in October 2025.
The important point is not simply the speed of that growth, but the emergence of three different revenue streams at the same time. NHS prescription dispensing contributed an annualised turnover run rate above £5.5 million, the recently launched New Health weight-management clinic was running above £2.2 million, and the acquired eMARx software business added approximately £843,000 of annualised subscription revenue. MedPal describes all three as recurring because they arise from repeat NHS prescriptions, continuing private treatment plans and monthly software subscriptions.
This represents a considerable change from the company described in its financial accounts as principally engaged in developing artificial-intelligence technology for healthcare. MedPal now operates pharmacy dispensing hubs, a private prescribing service, care-home medication software and the customer-facing digital tools intended to connect those activities. The strategy is no longer based on selling access to a standalone AI application, but on using technology to support and link clinical consultations, prescribing, dispensing, medication administration and patient follow-up.
That distinction matters because healthcare technology businesses often struggle to convert user engagement into dependable revenue. MedPal is attempting to avoid that problem by owning or controlling more of the transaction that follows a patient’s initial digital interaction. The opportunity is to build a connected healthcare platform in which technology helps attract and retain customers, while prescriptions, pharmacy services and software generate the underlying income.
Pharmacy Dispensing Provides the Revenue Foundation
The pharmacy operation currently provides the largest and most established part of MedPal’s revenue base. The group dispensed a record 47,223 NHS prescription items during July, an increase of 11.8% over the previous monthly record of 42,250 items set in May. At that level, MedPal said its NHS prescription business was operating at an annualised turnover run rate above £5.5 million.
That growth has been built through the recovery and development of pharmacy assets rather than through the purchase of mature revenue that continued automatically. MedPal acquired Universal pharmacy Ltd in September 2025 and subsequently completed the £310,000 acquisition of the former Remedi pharmacy assets in Runcorn. The Runcorn site had dispensed more than one million prescription items during 2024, equivalent to roughly £10 million of historical annualised turnover at current average NHS item values, but Remedi had entered administration and MedPal needed to rebuild the patient base.
The company’s approach has been to contact and reactivate patients whose previous dispensing arrangements had been disrupted, while bringing the recovered volume onto a shared technology and clinical infrastructure. This makes the historical Remedi figures useful as an indication of capacity and addressable demand, but not as revenue MedPal inherited intact. July’s record dispensing volume is therefore more meaningful because it reflects activity actually restored or generated under MedPal’s ownership.
The Runcorn operation also gives MedPal the physical capacity required for further expansion. Its larger approved dispensing facility is intended to use robotic automation to process growing NHS, private and care-home prescription volumes with less manual handling. The commercial test will be whether rising item numbers translate into better labour efficiency, stronger gross profit and progress towards the company’s stated pharmacy EBITDA break-even level of approximately 80,000 items per month.
New Health Creates a Second Consumer Revenue Engine
While NHS dispensing provides MedPal’s operating foundation, New Health gives the group a direct route into private consumer healthcare. The specialist brand was launched in May to focus initially on prescription weight-management treatments, with a separate website, marketing identity and patient journey. Behind that consumer-facing service sit MedPal’s existing clinical assessment, prescribing and pharmacy infrastructure.
The early commercial response has been notable. Following only three weeks of active marketing, New Health generated more than £180,000 of private prescription revenue during July, equivalent to an annualised run rate above £2.2 million. The company views this as recurring revenue because eligible patients generally follow monthly treatment plans rather than making a single purchase.
In practical terms, the service is designed to guide a prospective patient through an online intake process, clinical assessment and, where medically appropriate, prescription and dispensing. MedPal has committed £1.3 million to a six-month national marketing campaign, with spending intended to be adjusted according to consultation volumes, customer acquisition costs, retention and gross contribution. The speed of July’s growth is encouraging, but those longer-term measures will determine whether the business is creating durable value rather than simply converting a large advertising budget into short-lived sales.
The UK approval of the first oral GLP-1 treatment for weight management may broaden the potential market by offering a tablet-based alternative for people reluctant to use injectable treatments. Access is currently through private prescribing while the medicine awaits evaluation from the National Institute for Health and Care Excellence (NICE) for possible NHS use, placing New Health within the available commercial channel. The opportunity may be considerable, but MedPal must still demonstrate sustained patient demand, retention, reliable medicine supply and attractive margins after marketing and clinical costs.
eMARx Adds High-Margin Software and Completes the Care-Home Model
MedPal’s acquisition of eMARx adds a different type of income to the group. Rather than earning revenue from dispensing medicines, eMARx charges recurring subscriptions for software used by care homes and pharmacies to manage medication administration. Each resident’s doses can be scheduled, verified and recorded digitally, replacing paper-based charts with a live and auditable record.
The acquired company generated unaudited revenue of approximately £739,000 and profit after tax of £106,000 in the year to 31st March 2026. Revenue had risen by 19% during the year and had approximately trebled over three years, while the business reported a gross margin of around 82%. MedPal agreed an expected total consideration of approximately £474,000, paid through a combination of cash and new shares, making eMARx relatively small in acquisition cost but potentially significant in strategic value.
The attraction lies in connecting the software with MedPal’s care-home pharmacy operation. A care home using eMARx is already managing substantial volumes of repeat medication, making it a natural potential customer for MedPal’s dispensing service. In the other direction, a care home supplied by MedPal can be offered eMARx at a reduced cost, or potentially without a separate charge, in return for using the group as its exclusive pharmacy provider.
That creates a clearer commercial purpose than simply adding another software product. MedPal can now attempt to manage the full medication process, from pharmacy dispensing and delivery through to the digital record used when the medicine is administered to a resident. The model could improve customer retention and generate higher-margin subscription income alongside pharmacy turnover, but its success will depend on how effectively MedPal converts eMARx’s installed customer base into dispensing relationships without damaging the software business’s existing economics.
Health OS Connects the Separate Businesses into One System
The MedPal Health OS is the framework intended to turn the group’s different services into one connected healthcare journey. Rather than treating the app, clinic and pharmacy as separate businesses, MedPal wants information to move between them. A user’s health data can help identify a possible concern, support a clinical consultation and, where appropriate, lead to a prescription that is dispensed through the company’s pharmacy operation.
The app can bring together information from more than 100 wearable devices and health applications, including data relating to activity, sleep and heart rate. MedPal’s at-home blood-testing service adds another layer by placing laboratory biomarker results beside the continuous information collected from wearables. The first test was designed for people using GLP-1 weight-management medicines, with samples analysed by a UKAS-accredited laboratory and results delivered through the app.
Where the data suggests that medical attention may be needed, the system can direct the user towards MedPal’s clinical services. A qualified clinician remains responsible for assessing the patient and deciding whether treatment or a prescription is appropriate. Medication can then be processed through the group’s automated dispensing infrastructure, after which further health information can be used to monitor the patient’s response.
This connected pathway is the commercial purpose of Health OS. MedPal is trying to move customers from occasional use of a wellness app into longer relationships involving consultations, testing, repeat prescriptions and pharmacy fulfilment. The technology may make that journey easier, but the value of the system will ultimately depend on whether it produces more active customers, stronger retention and greater revenue per user without allowing clinical and operating costs to rise at the same pace.
Juno Gives the AI Strategy a Practical Role
Juno is the customer-facing AI companion intended to guide people through the Health OS. MedPal describes it as an agentic system, meaning that it is designed not only to answer questions but also to monitor available health information and contact a user when it identifies something that may require attention. Patients can communicate with it through text-based services, including the web and WhatsApp.
The company has moved the conversational and reasoning functions behind Juno to Anthropic’s Claude models, while its clinical response layers operate on dedicated DigitalOcean infrastructure. In plain terms, the AI helps interpret questions and organise the next step, but it does not replace the doctor. Where clinical action may be required, Juno is designed to connect the patient with one of MedPal’s clinicians, who remains responsible for diagnosis and prescribing.
That connection gives Juno a more practical role than a general health chatbot. A conventional AI assistant may explain symptoms or provide broad information, but it cannot itself arrange a regulated treatment pathway. MedPal’s model is intended to continue from initial advice through clinical assessment, pharmacy dispensing and delivery, with Juno subsequently checking how the patient is progressing.
The investment case should not, however, depend on the sophistication of the AI alone. Juno must demonstrate that it can attract users, direct them safely towards appropriate services and improve the efficiency of MedPal’s clinical and pharmacy operations. Evidence of higher conversion, repeat use, customer retention and lower service costs would show that Juno is becoming a commercial asset rather than simply a technically interesting feature.
Cross-Selling Could Become MedPal’s Main Competitive Advantage
The commercial logic behind MedPal’s acquisitions and product launches is that the same customer can use more than one part of the group. A patient attracted through New Health may initially use MedPal for a private weight-management prescription, but can also be invited to nominate the group’s pharmacy for routine NHS medicines. The same person could later use at-home blood testing, Health OS and Juno, allowing one customer relationship to support several recurring revenue streams. MedPal identified this cross-selling strategy explicitly in its July trading update.
A similar opportunity exists within the care-home market. eMARx already supplies electronic medication-administration software to care homes and pharmacies, placing it at the point where medicines are recorded and given to residents. MedPal can offer those customers its dispensing service, while pharmacy clients can be encouraged to adopt eMARx, creating a more complete relationship than either business could offer independently. The acquisition therefore links recurring software subscriptions with MedPal’s pharmacy supply operation.
This could become a meaningful advantage because customer acquisition is one of the largest costs in digital healthcare. MedPal spent more than £1.07 million on advertising and marketing during the six months to February 2026, against revenue of £1.60 million for the period. A customer who uses several services may therefore produce a better return on that initial marketing expenditure than one who purchases only a single prescription or consultation.
The opportunity should not be confused with proven performance. MedPal must still demonstrate how many private patients convert into NHS pharmacy customers, how successfully eMARx users can be transferred into dispensing relationships and whether customers continue using the wider platform after their initial treatment. Cross-selling is currently a credible strategic advantage, but its financial value will only become clear through conversion, retention and revenue-per-customer data.
Rapid Growth Has Required Substantial Capital and Dilution
MedPal’s expansion has required considerably more capital than the revenue headline alone might suggest. For the six months to 28th February 2026, the group reported revenue of £1.60 million and gross profit of £368,550, but administrative expenses reached £3.36 million and the loss for the period was £3.27 million. Net cash used in operating activities was approximately £3.71 million, leaving only £4,189 of cash at the reporting date.
The company has since repaired that position through repeated equity funding. It raised £3 million in April and then completed a further £5 million placing in July at 3.5p per share. The July funding was intended to complete the eMARx acquisition, invest up to approximately £3 million in oral GLP-1 stock and patient acquisition, and provide working capital for the growing pharmacy and care-home operations.
The positive interpretation is that MedPal raised the July money at a 40% premium to the 2.5p price used for the April placing, reflecting the operational progress achieved between the two transactions. The less favourable point is that the July placing and related settlement shares added almost 154 million new shares. Following a further issue of advisory shares, the company said its issued share capital would reach approximately 778 million shares, compared with 413 million at the end of August 2025.
That increase means investors must judge performance on a per-share basis rather than looking only at group revenue. The acquisitions, marketing expenditure and operating investment may prove worthwhile if they produce durable gross profit and cash generation greater than the dilution incurred. Until that happens, MedPal remains dependent on the capital markets to fund a strategy that is growing quickly but has not yet demonstrated financial self-sufficiency.
The Next Phase Is About Converting Momentum into Cash Generation
MedPal has moved well beyond being an early-stage company with an AI healthcare idea. It now operates NHS dispensing facilities, a rapidly growing private clinic, care-home pharmacy services and an established software subscription business. Its July performance, including 47,223 NHS prescription items, more than £180,000 of private prescription revenue and approximately £843,000 of annualised eMARx revenue, provides evidence that all three commercial engines are operating at the same time. The group placed its annualised recurring revenue run rate above £8.6 million.
That figure is important, but it should be interpreted carefully. It annualises one month’s trading and is not the same as £8.6 million of recognised revenue over a completed year. New Health had been actively marketed for only three weeks, eMARx had only just joined the group, and the pharmacy operation was still rebuilding volumes and moving towards a larger automated facility. The next several months will show whether July represented a sustainable base or an early surge assisted by launches, marketing and acquisitions.
The most useful measures will now be monthly dispensing volume, private-patient retention, gross contribution after marketing costs, the number of eMARx customers adopting MedPal dispensing and progress towards pharmacy break-even. Investors will also need clearer evidence that Health OS and Juno improve conversion or operating efficiency, rather than simply expanding the range of products the company offers.
The investment case has strengthened because MedPal now has operating revenue, physical pharmacy infrastructure and a clearer commercial role for its technology. The remaining challenge is equally clear: it must turn fast revenue growth into improving margins, reduced cash consumption and eventually a business capable of funding its own expansion. MedPal has assembled the parts of a vertically integrated healthcare platform; the next phase will determine whether those parts combine into a sustainable and valuable whole.
Disclaimer: The information presented in this article represents the opinions and research of the author and is provided for informational purposes only. It is not intended to be, nor should it be interpreted as, financial, investment, or legal advice. Investors are encouraged to perform their own due diligence and consult with qualified financial advisors before making any investment decisions. Investing in small-cap stocks involves significant risks, and past performance is not indicative of future results. The author and publisher are not liable for any financial losses or actions taken based on the content of this article.
